A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Guselkumab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms APEX
- Sponsors Janssen Research & Development; Janssen-Cilag
- 30 May 2023 Planned primary completion date changed from 25 Dec 2023 to 10 Jan 2025.
- 14 Mar 2023 Planned End Date changed from 27 Nov 2027 to 8 Dec 2027.
- 10 Jan 2023 Results assessing the effect of guselkumab on radiographic progression in patients with active psoriatic arthritis and risk factors for radiographic progression, published in the Trials.